共 50 条
- [41] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Fedyanin, MikhailTryakin, AlexeyLisyanskaya, Alla SergeevnaSolovyeva, EkaterinaFadeeva, NataliaGladkov, OlegMoiseyenko, VladimirCheporov, Sergey, VShpigotskaya, PolinaPurmal, AndreiMiller, Langdon L.Leonov, AndreyZakurdaeva, KristinaGurova, KaterinaGudkov, AndreiTjulandin, Sergei
- [42] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsInvestigational New Drugs, 2016, 34 : 216 - 224Jeffrey R. InfanteDavid S. MendelsonHoward A. BurrisJohanna C. BendellAnthony W. TolcherMichael S. GordonHeidi H. GillenwaterShirin Arastu-KapurHansen L. WongKyriakos P. Papadopoulos
- [43] First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)De Bono, Johann S.Tan, David Shao PengCaldwell, ReeceTerbuch, AngelikaGoh, Boon C.Heong, ValerieHaris, Noor MdBashir, SairaHong, David S.Meric-Bernstam, FundaBordia, SonalLiu, LiWilkinson, GaryHreiki, JosephWengner, AntjeFischer, KerstinBoix, OliverLagkadinou, EleniPlummer, ElizabethYap, Timothy A.
- [44] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Burris, H.Rodon, J.Sharma, S.Herbst, R. S.Tabernero, J.Infante, J. R.Silva, A.Demanse, D.Hackl, W.Baselga, J.
- [45] First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsMOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 531 - 540Shimomura, AkihikoYamamoto, NoboruKondol, ShunsukeFujiwara, YutakaSuzuki, ShigenobuYanagitani, NorikoHoriike, AtsushiKitazono, SatoruOhyanagi, FumiyoshiDoi, ToshihikoKuboki, YasutoshiKawazoe, AkihitoShitara, KoheiOhno, IzumiBanerji, UdaiSundar, RaghavOhkubo, ShuichiCalleja, Elizabeth M.Nishio, Makoto
- [46] First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Papadopoulos, Kyriakos P.Sharma, ManishHamilton, Erika PaigeRichardson, Debra L.Hodgson, GraemeZhou, LiVolkert, AngelaJolin, Hina A.Madigan, CatherineKelly, MichaelRoth, David A.
- [47] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Voss, Martin HennerHierro, CintaHeist, Rebecca SukCleary, James M.Meric-Bernstam, FundaGandhi, LeenaIshii, NobuyaKirpicheva, YuliaNicolas-Metral, ValeriePokorska-Bocci, AnnaPurcea, DanielaVaslin, AnneMoulon, CorinneZanna, ClaudioFlaherty, KeithTabernero, JosepBaselga, Jose
- [48] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.CANCER RESEARCH, 2022, 82 (12)Johnson, MelissaUlahannan, SusannaVandross, AndraePark, HaeseongFaoro, LeoFaggioni, RaffaellaLi, JingChang, Yu-LinUttamsingh, ShailajaTolcher, Anthony
- [49] Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors.CANCER RESEARCH, 2021, 81 (13)Powderly, JohnShimizu, ToshioLoRusso, PatriciaRazak, AlbiruniMiller, KathyBalar, ArjunBruix, JordiMichel, LorenBlaney, MarthaGuan, XiaowenLacy, SusanLally, SatwantLambert, StacieLeibman, RachelVosganian, GregoryGolan, TaliaTolcher, Anthony
- [50] A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wei, Xiao-LiXu, Rui-huaZhao, HongyunZhang, YangZou, Ben-YanWang, FengLiu, JihongWang, ZhiqiangQiu, Miao-ZhenYu, QiuqiongLiu, Yun